<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348659</url>
  </required_header>
  <id_info>
    <org_study_id>R09246M</org_study_id>
    <secondary_id>2010-019352-42</secondary_id>
    <nct_id>NCT01348659</nct_id>
  </id_info>
  <brief_title>Effects of Hypertonic Saline-HES Solution on Extracellular Water in Cardiac Surgery Patients</brief_title>
  <official_title>Effects of Hypertonic Saline-hydroxyethyl Starch Solution on Extracellular Water in Cardiac Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kati Järvelä</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Finnish Cultural Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to describe the effects of hypertonic saline/hydroxyethylstarch&#xD;
      solution in comparison to saline solution for 25 + 25 patients undergoing coronary bypass&#xD;
      grafting surgery (CABG) using CPB. The study fluid will be given into the venous reservoir of&#xD;
      the CPB circuit after aortic declamping. Primary endpoints are the changes in body weight and&#xD;
      extracellular water from baseline to the first postoperative morning.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiac surgery and cardiopulmonary bypass (CPB) cause fluid retention in the body. Both&#xD;
      dilution of serum proteins and destruction of vascular endothelial glycocalyx cause&#xD;
      extravasation of the fluids. We cannot avoid this phenomenon but we can try to restore the&#xD;
      excess fluid into the intravascular space where it can be excreted via the kidneys.&#xD;
&#xD;
      Hypertonic saline (HS) creates an osmotic gradient across the cellular membrane, causing a&#xD;
      fluid shift from the intracellular space into the extracellular space and from the&#xD;
      extravascular space into the intravascular space. The intravascular hypertonic benefit is&#xD;
      short-lasting as a result of redistribution of fluid between the intravascular and&#xD;
      interstitial spaces. The effect can be lengthened by adding colloid component into the&#xD;
      solution.&#xD;
&#xD;
      The aim of the study is to describe the effects of hypertonic saline/hydroxyethylstarch&#xD;
      solution in comparison to saline solution for 25 + 25 patients undergoing coronary bypass&#xD;
      grafting surgery (CABG) using CPB. The study fluid will be given into the venous reservoir of&#xD;
      the CPB circuit after aortic declamping. Primary endpoints are the changes in body weight and&#xD;
      extracellular water from baseline to the first postoperative morning. Secondary endpoints are&#xD;
      the need of fluids and diuretic medication during the perioperative period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in extracellular water from baseline to the first postoperative morning.</measure>
    <time_frame>24h</time_frame>
    <description>Perioperative fluid balance will be assessed by measuring changes in body weight and extracellular water from baseline to the first postoperative morning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need of fluids during the day of surgery.</measure>
    <time_frame>24h</time_frame>
    <description>Need of fluids and diuretic medication during the day of surgery until the first postoperative morning will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Fluid Volume Disorder</condition>
  <arm_group>
    <arm_group_label>7.2% NaCl/hydroxyethyl starch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) (Hyperhaes®, Fresenius Kabi)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% NaCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>250 ml of NaCl 0.9% (Natriumklorid Braun 9 mg/ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7.2% NaCl/hydroxyethylstarch</intervention_name>
    <description>250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) will be given into the venous reservoir of the cardiopulmonary bypass circuit after aortic declamping.</description>
    <arm_group_label>7.2% NaCl/hydroxyethyl starch</arm_group_label>
    <other_name>Hyperhaes®, Fresenius Kabi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9%</intervention_name>
    <description>250 ml of NaCl 0.9% will be given into the venous reservoir of the CPB circuit after aortic declamping.</description>
    <arm_group_label>0.9% NaCl</arm_group_label>
    <other_name>Natriumklorid Braun 9 mg/ml</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male gender and no need for pulmonary artery catheter (pulmonary hypertension or left&#xD;
             ventricular ejection fraction &lt; 40%).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic hyponatremia and significant renal dysfunction.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kati Järvelä, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital Heart Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tampere University Hospital Heart Center</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <last_update_submitted>May 4, 2012</last_update_submitted>
  <last_update_submitted_qc>May 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tampere University Hospital</investigator_affiliation>
    <investigator_full_name>Kati Järvelä</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Hypertonic saline</keyword>
  <keyword>Extracellular fluid</keyword>
  <keyword>cardiopulmonary bypass</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

